Patents by Inventor Otto Phanstiel, IV
Otto Phanstiel, IV has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9346741Abstract: Disclosed herein are di-substituted aryl polyamine compounds and methods of making and using the same. The di-substituted polyamine compounds act as PTS targeting agents, which selectively target the polyamine transport system (PTS) with high efficacy and have improved stability in the presence of amine oxidases.Type: GrantFiled: March 14, 2013Date of Patent: May 24, 2016Assignee: University of Central Florida Research Foundation, Inc.Inventors: Otto Phanstiel, IV, Aaron Muth
-
Publication number: 20160075633Abstract: Several aromatic hydrocarbons di-substituted with a polyamine are described according to formulas selected from compounds 4, 7, 10, 15 and pharmaceutically acceptable salts thereof. The novel dimeric polyamines of the present invention demonstrate enhanced penetration into cells having an upregulated polyamine transport system, such as various types of cancer cells. The disclosed aromatic polyamine dimers provide highly efficient drugs for targeting cancer cells with active polyamine transporters.Type: ApplicationFiled: September 23, 2015Publication date: March 17, 2016Applicant: University of Central Florida Research Foundation, Inc.Inventor: Otto Phanstiel, IV
-
Patent number: 9285320Abstract: Cyano-substituted anthracene containing polyamines were synthesized and shown to be efficient polyamine transporter ligands. Moreover, these compounds (3 and 4) had improved fluorescence properties over previously known anthryl-polyamine conjugates, which facilitated their intracellular trafficking by confocal microscopy and fluorescence methods. These cytotoxic fluorescent agents may find use as molecular probes which traffic into cells via the polyamine transport system and may also be viable anticancer drugs which are readily quantified in human tissues due to their excellent fluorescence properties: (excitation: ? 405 nm) and emission (420 nm) occurs in the visible light range. The ability to excite and emit in the visible range provides an advantage to these probes as these wavelengths are considered non-toxic to human cells (versus ultraviolet mediated excitations, ?<400 nm) and visible light lasers are less costly to purchase and operate than UV laser sources.Type: GrantFiled: March 15, 2013Date of Patent: March 15, 2016Assignee: University of Central Florida Research Foundation, Inc.Inventor: Otto Phanstiel, IV
-
Patent number: 9266815Abstract: Disclosed herein are novel motuporamine compounds that act as anti-metastatic agents with low toxicity and high anti-migration activity. The non-toxic, anti-metastatic agents may be given to patients with potential or actual metastatic cancers, such as pancreatic cancers, alone in combination with known and/or new therapies to help block the growth and spread of tumor(s).Type: GrantFiled: March 13, 2013Date of Patent: February 23, 2016Assignee: University of Central Florida Research Foundation, Inc.Inventors: Otto Phanstiel, IV, Aaron Muth
-
Patent number: 9150495Abstract: Several aromatic hydrocarbons di-substituted with a polyamine are described according to formulas selected from compounds 4, 7, 10, 15 and pharmaceutically acceptable salts thereof. The novel dimeric polyamines of the present invention demonstrate enhanced penetration into cells having an upregulated polyamine transport system, such as various types of cancer cells. The disclosed aromatic polyamine dimers provide highly efficient drugs for targeting cancer cells with active polyamine transporters.Type: GrantFiled: July 29, 2013Date of Patent: October 6, 2015Assignee: University of Central Florida Research Foundation, Inc.Inventor: Otto Phanstiel, IV
-
Publication number: 20150209323Abstract: The present invention relates to novel compounds for modulating US28 receptor activity and methods for their use in preventing or treating US28 receptor-mediated disorders or conditions.Type: ApplicationFiled: September 23, 2013Publication date: July 30, 2015Applicants: University of Central Florida Research Foundation,, Friedrich Alexander UniversityInventors: Otto Phanstiel, IV, Nuska Tschammer
-
Publication number: 20150057361Abstract: Disclosed herein are novel motuporamine compounds that act as anti-metastatic agents with low toxicity and high anti-migration activity. The non-toxic, anti-metastatic agents may be given to patients with potential or actual metastatic cancers, such as pancreatic cancers, alone in combination with known and/or new therapies to help block the growth and spread of tumor(s).Type: ApplicationFiled: March 13, 2013Publication date: February 26, 2015Applicant: University of Central Florida Research Foundation, Inc.Inventors: Otto Phanstiel, IV, Aaron Muth
-
Publication number: 20150017231Abstract: Disclosed herein are di-substituted aryl polyamine compounds and methods of making and using the same. The di-substituted polyamine compounds act as PTS targeting agents, which selectively target the polyamine transport system (PTS) with high efficacy and have improved stability in the presence of amine oxidases.Type: ApplicationFiled: March 14, 2013Publication date: January 15, 2015Applicant: University of Central Florida Research Foundation, Inc.Inventors: Otto Phanstiel, IV, Aaron Muth
-
Publication number: 20140057989Abstract: Several aromatic hydrocarbons di-substituted with a polyamine are described according to formulas selected from compounds 4, 7, 10, 15 and pharmaceutically acceptable salts thereof. The novel dimeric polyamines of the present invention demonstrate enhanced penetration into cells having an upregulated polyamine transport system, such as various types of cancer cells. The disclosed aromatic polyamine dimers provide highly efficient drugs for targeting cancer cells with active polyamine transporters.Type: ApplicationFiled: July 29, 2013Publication date: February 27, 2014Applicant: University of Central Florida Research Foundation, Inc.Inventor: Otto Phanstiel, IV
-
Publication number: 20130337494Abstract: Cyano-substituted anthracene containing polyamines were synthesized and shown to be efficient polyamine transporter ligands. Moreover, these compounds (3 and 4) had improved fluorescence properties over previously known anthryl-polyamine conjugates, which facilitated their intracellular trafficking by confocal microscopy and fluorescence methods. These cytotoxic fluorescent agents may find use as molecular probes which traffic into cells via the polyamine transport system and may also be viable anticancer drugs which are readily quantified in human tissues due to their excellent fluorescence properties: (excitation: ?405 nm) and emission (420 nm) occurs in the visible light range. The ability to excite and emit in the visible range provides an advantage to these probes as these wavelengths are considered non-toxic to human cells (versus ultraviolet mediated excitations, ?<400 nm) and visible light lasers are less costly to purchase and operate than UV laser sources.Type: ApplicationFiled: March 15, 2013Publication date: December 19, 2013Applicant: University of Central Florida Research Foundation, Inc.Inventor: Otto Phanstiel, IV
-
Publication number: 20130289278Abstract: Disclosed embodiments relate to improved methods for the synthesis of activated fumarate intermediates and their use in chemical synthesis. Disclosed embodiments describe the synthesis of activated fumarate esters including those derived from activating groups including: 4-nitrophenyl, diphenylphosphoryl azide, pivaloyl chloride, chlorosulfonyl isocyanate, p-nitrophenol, MEF, trifluoroacetyl and chlorine, for example, ethyl fumaroyl chloride and the subsequent use of the activated ester in situ. Further embodiments describe the improved synthesis of substituted aminoalkyl-diketopiperazines from unisolated and unpurified intermediates allowing for improved yields and reactor throughput.Type: ApplicationFiled: March 15, 2013Publication date: October 31, 2013Applicant: MANNKIND CORPInventors: Kelly Sullivan Kraft, John J. Freeman, Paul Serwinski, Vinnie Pavia, Otto Phanstiel, IV, Navneet Kaur
-
Patent number: 8497398Abstract: Several aromatic hydrocarbons di-substituted with a polyamine are described according to formulas selected from compounds 4, 7, 10, 15 and pharmaceutically acceptable salts thereof. The novel dimeric polyamines of the present invention demonstrate enhanced penetration into cells having an upregulated polyamine transport system, such as various types of cancer cells. The disclosed aromatic polyamine dimers provide highly efficient drugs for targeting cancer cells with active polyamine transporters.Type: GrantFiled: May 1, 2008Date of Patent: July 30, 2013Assignee: University of Central Florida Research Foundation, Inc.Inventors: Otto Phanstiel, IV, Navneet Kaur
-
Patent number: 8410311Abstract: Cyano-substituted anthracene containing polyamines were synthesized and shown to be efficient polyamine transporter ligands. Moreover, these compounds (3 and 4) had improved fluorescence properties over previously known anthryl-polyamine conjugates, which facilitated their intracellular trafficking by confocal microscopy. These cytotoxic fluorescent agents may find use as molecular probes which traffic into cells via the polyamine transport system and may also be viable anticancer drugs which are readily quantified in human tissues due to their excellent fluorescence properties: (excitation: ? 405 nm) and emission (420 nm) occurs in the visible light range. The ability to excite and emit in the visible range provides an advantage to these probes as these wavelengths are not toxic to human cells (versus ultraviolet mediated excitations, ?<400 nm) and visible light lasers are less costly to purchase and operate than UV laser sources.Type: GrantFiled: April 6, 2010Date of Patent: April 2, 2013Assignee: University of Central Florida Research Foundation, Inc.Inventor: Otto Phanstiel, IV
-
Patent number: 7972807Abstract: Disclosed are diagnostic tests helpful in indicating presence of an inflammatory bowel disease (IBD) in a human patient. In one embodiment, the test comprises obtaining a sample of mucosal tissue from the ileum or sigmoid colon of the patient; evaluating sample quality by testing for cadaverine and continuing the diagnostic test if the sample has no detectable cadaverine; testing the cadaverine negative sample for N-acetylated spermine; and correlating a detectable level of N-acetylated spermine in the sample with presence of IBD in the patient. Another, less invasive, method disclosed includes a diagnostic test comprising isolating mononuclear leukocytes from the patient's blood; testing the isolated mononuclear leukocytes for level of spermidine; and correlating a level of spermidine higher than that in mononuclear leukocytes of normal subjects as indicative of an inflammatory bowel disease in the patient.Type: GrantFiled: June 16, 2008Date of Patent: July 5, 2011Assignee: University of Central Florida Research Foundation, Inc.Inventors: Otto Phanstiel, IV, Navneet Kaur
-
Patent number: 7910363Abstract: Polyamine cationic lipids have been synthesized that have the ability to be transported into cells having an active polyamine transport system. Accordingly, these lipids may be conjugated with various agents and, thereby, act as vectors for transporting the agent into the cell aided by the cell's own polyamine transport system. A method of delivering an agent into a cell includes associating the agent with a polyamine cationic lipid selected from compounds 25, 26, 27, 28, their pharmaceutically acceptable salts and combinations thereof and contacting the cell therewith.Type: GrantFiled: May 2, 2008Date of Patent: March 22, 2011Assignee: University of Central Florida Research Foundation, Inc.Inventors: Otto Phanstiel, IV, Ken Teter
-
Patent number: 5162448Abstract: Ortho ester-capped polyphenylene ethers are prepared by the reaction of a polyphenylene ether with a reactive compound containing an ortho ester group, preferably a 4-(2-methoxy-2-methyl-1,3-dioxolane-4-yl)methyl group. Chlorotriazines containing the ortho ester substituent are particularly preferred as capping agents. The capped polyphenylene ethers form copolymer-containing compositions with polyesters and other polymers containing carboxylic acid groups.Type: GrantFiled: December 19, 1991Date of Patent: November 10, 1992Assignee: General Electric CompanyInventors: Farid F. Khouri, Otto Phanstiel, IV
-
Patent number: 5142049Abstract: Ortho ester-substituted chlorotriazines are prepared by the reaction of a dichlorotriazine with a reactive compound containing an ortho ester group, preferably a 4-(2-methoxy-2-methyl-1,3-dioxolan-4-yl)methyl group. They are useful as capping agents for polyphenylene ethers. The capped polyphenylene ethers form copolymer-containing compositions with polyesters, polyamides and other polymers containing carboxylic acid or amine groups.Type: GrantFiled: August 15, 1990Date of Patent: August 25, 1992Assignee: General Electric CompanyInventors: Farid F. Khouri, John T. Jackman, Otto Phanstiel, IV
-
Patent number: 5132373Abstract: Ortho ester-capped polyphenylene ethers are prepared by the reaction of a polyphenylene ether with a reactive compound containing an ortho ester group, preferably a 4-(2-methoxy-2-methyl-1,3-dioxolan-4-yl)methyl group. Chlorotriazines containing the ortho ester substituent are particularly preferred as capping agents. The capped polyphenylene ethers form copolymer-containing compositions with polyesters and other polymers containing carboxylic acid groups.Type: GrantFiled: August 13, 1990Date of Patent: July 21, 1992Assignee: General Electric CompanyInventors: Farid F. Khouri, Otto Phanstiel, IV, Sterling B. Brown, John T. Jackman